Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Mutations in the dim light photoreceptor protein rod opsin cause autosomal dominant retinitis pigmentosa. The majority of these mutations (class II) lead to protein misfolding. For example, the common class II rod opsin mutation P23H misfolds and is retained in the ER, prior to retrotranslocation and degradation by the proteasome. If degradation fails then the protein can aggregate to form intracellular inclusions. Furthermore, mutant opsin exerts a dominant negative effect on the wild-type (WT) protein. Here we show that the toxic gain of function and dominant negative properties of misfolded rod opsin in cells can be alleviated by drug treatments targeted against a range of cellular pathways. P23H rod opsin aggregation, inclusion formation with associated caspase activation and cell death were reduced by kosmotropes, molecular chaperone inducers and mToR inhibition. But these treatments did not enhance mutant opsin folding or reduce the dominant negative effect of P23H rod opsin. In contrast, retinoids acted as pharmacological chaperones to enhance P23H folding and reduce the dominant negative effect on WT rod opsin processing, as well as reducing toxic gains of function. Therefore, the suppression of the dominant negative effects of protein misfolding required enhanced folding of the mutant protein, whereas suppression of toxic gain of function effects did not require improved folding per se. These studies suggest that some forms of rhodopsin RP may be treated by targeting protein folding and reducing protein aggregation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495 · cited 1×
“aggregation, increasing degradation or protection from cell death ( 15 ).”
BackgroundRavikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 1×
“Treatment with rapamycin protected against neurodegeneration and the rapamycin analogue CCI-779 improved the performance in behavioural tasks and decreased the size and frequency of inclusions in a mouse model of Huntington disease (26).”
BackgroundSarkar, S., Davies, J. E., Huang, Z., Tunnacliffe, A., & Rubinsztein, D. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609532200 · Cited by 1,142
Retinopathy induced in mice by targeted disruption of the rhodopsin gene
Humphries, M. M., Rancourt, D., Farrar, G. J., Kenna, P., Hazel, M., Bush, R. A., Sieving, P. A., Sheils, D. M., Creighton, P., Erven, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-216 · Cited by 529 · cited 1×
“There are several lines of evidence suggesting that the loss of function (haploinsufficiency) is not likely to be the mechanism leading to photoreceptor cell death, as heterozygous rhodopsin-knockout mice showed little photoreceptor degeneration (7,8) suggesting that the mechanism of cell death induced by Class II mut…”
BackgroundSittler, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1307 · Cited by 442 · cited 1×
“Treatment of COS-1 cells with geldanamycin induced the expression of Hsp40, Hsp70 and Hsp90 and inhibited aggregation of polyglutamine expanded Huntingtin exon 1 protein (23).”
Background17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration
Waza, M., Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Tanaka, F., Inukai, A., Doyu, M., & Sobue, G. (2005) · Nature Medicine · doi:10.1038/nm1298 · Cited by 395
Cited by
Athanasiou, D., Aguila, M., Bellingham, J., Li, W., McCulley, C., Reeves, P. J., & Cheetham, M. E. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.002 · Cited by 373
Self-citationMolecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J. (2019) · Genes · doi:10.3390/genes10090654 · Cited by 80
Inactivation of VCP/ter94 Suppresses Retinal Pathology Caused by Misfolded Rhodopsin in Drosophila
Griciuc, A., Aron, L., Roux, M. J., Klein, R., Giangrande, A., & Ueffing, M. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001075 · Cited by 78
TRAP1 in Oxidative Stress and Neurodegeneration
Ramos Rego, I., Santos Cruz, B., Ambrósio, A. F., & Alves, C. H. (2021) · Antioxidants · doi:10.3390/antiox10111829 · Cited by 44
Daich Varela, M., Georgiadis, A., & Michaelides, M. (2023) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-321903 · Cited by 30
Metadata
- Authors
- Mendes, H. F., & Cheetham, M. E.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-07-17
- Volume
- 17
- Issue
- 19
- Pages
- 3043-3054
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2137101268
- Cited by
- 137
- References
- 6
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.